title: Optimum timing of treatment for hepatitis C infection relative to liver transplantation.
abstract: The approval of direct-acting antiviral agents that may be given orally in an interferon-free regimen has greatly changed the landscape of treatment for hepatitis C virus (HCV) infection, especially for patients with the most severe disease, who have decompensated cirrhosis, or who are waiting for or have undergone liver transplantation. Treatment with interferon proved to be ineffective and poorly tolerated because of high risks of infection and transplant rejection. The availability of new drugs poses new questions about the optimum time to give treatment to prevent HCV recurrence, taking into account efficacy, tolerance, and drug-drug interactions. Treatment is acceptable before and after transplantation, but the two strategies have subtle differences. In this Review, we present the available data on the treatment of HCV infection before and after transplantation, and discuss new challenges for practice.
authors.affiliation: Department of Hepatology, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Hepatinov, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, Villejuif, France; INSERM, Unité 1193, Villejuif, France. Electronic address: audrey.coilly@aphp.fr.
authors.forename: Audrey
authors.initials: A
authors.lastname: Coilly
authors.affiliation: Department of Hepatology, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Hepatinov, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, Villejuif, France; INSERM, Unité 1193, Villejuif, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Roche
authors.affiliation: Department of Hepatology, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Hepatinov, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, Villejuif, France; INSERM, Unité 1193, Villejuif, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Duclos-Vallée
authors.affiliation: Department of Hepatology, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Hepatinov, Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, Villejuif, France; INSERM, Unité 1193, Villejuif, France.
authors.forename: Didier
authors.initials: D
authors.lastname: Samuel
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D058625:End Stage Liver Disease / Q000601:surgery* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation; D019990:Perioperative Care / Q000379:methods*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents